Black Rock Inc. Concert Pharmaceuticals, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$4.34 - $5.84 $1.78 Million - $2.4 Million	410,760 Added 49.72%	1,236,951 $7.22 Million
Q3 2022 Nov 14, 2022	BUY	$4.27 - $7.2 $1.67 Million - $2.81 Million	390,713 Added 89.72%	826,191 $5.54 Million
Q2 2022 Aug 12, 2022	SELL	$2.8 - $6.36 $34,916 - $79,309	-12,470 Reduced 2.78%	435,478 $1.83 Million
Q1 2022 May 12, 2022	SELL	$2.73 - $3.94 $9,393 - $13,557	-3,441 Reduced 0.76%	447,948 $1.51 Million
Q4 2021 Feb 10, 2022	SELL	$2.69 - $4.22 $722,490 - $1.13 Million	-268,584 Reduced 37.3%	451,389 $1.42 Million
Q3 2021 Nov 09, 2021	BUY	$3.17 - $4.15 $158,303 - $207,242	49,938 Added 7.45%	719,973 $2.36 Million
Q2 2021 Aug 11, 2021	BUY	$3.77 - $5.24 $2.53 Million - $3.51 Million	670,035 New	670,035 $2.83 Million

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.